ANDA 205630, held by Lupin. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 205630 (Norgestimate And Ethinyl Estradiol), held by Lupin, was first approved by FDA on Oct 27, 2016, with 4 approved supplements and 0 published complete response letters.
Norgestimate and ethinyl estradiol tablet is a combination of norgestimate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. 1.1 Oral Contraceptive
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 27, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norgestimate And Ethinyl Estradiol0.035MG;0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Mar 7, 2025 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 14, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 14, 2019 | Supplement 4Manufacturing | Approved | None posted |
| Oct 27, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters